Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses

Investigative Radiology

Volumn 49, Issue 8, 2014, Pages 524-531

  Tsuboyama, Takahiro ^a   Tatsumi, Mitsuaki ^a   Onishi, Hiromitsu ^a   Nakamoto, Atsushi ^a   Kim, Tonsok ^a   Hori, Masatoshi ^a   Sakane, Makoto ^a   Hori, Yumiko ^a   Morii, Eiichi ^a   Hatazawa, Jun ^a   Tomiyama, Noriyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Magnetic resonance imaging; Ovarian tumors; Positron emission tomography computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOTERIDOL; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; CONTRAST ENHANCEMENT; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; HYSTERECTOMY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OMENTECTOMY; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CARCINOMA; OVARY TERATOMA; OVARY TUMOR; PET-CT SCANNER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SEX CORD TUMOR; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; IMAGE ENHANCEMENT; METABOLISM; MIDDLE AGED; MULTIMODAL IMAGING; OVARIAN NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM; HETEROCYCLIC COMPOUNDS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIMODAL IMAGING; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904071397     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000050     Document Type: Article

References (40)

1. Covens AL, Dodge JE, Lacchetti C, et al. Surgical management of a suspicious adnexal mass: a systemic review. Gynecol Oncol. 2012;126:149Y156.
2. Cadron I, Leunen K, Van Gorp T, et al. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25:2928Y2937.
3. Imaoka I, Wada A, Kaji Y, et al. Developing an MR imaging strategy for diagnosis of ovarian masses. Radiographics. 2006;26:1431Y1448.
4. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imagingVmultivariate analysis. Radiology. 2000;214:39Y46.
5. Sohaib SA, Sahdev A, Van Trappen P, et al. Characterization of adnexal mass lesions on MR imaging. AJR Am J Roentogenol. 2003;180:1297Y1304.
6. Kim KA, Park CM, Lee JH, et al. Benign ovarian tumors with solid and cystic components that mimic malignancy. AJR Am J Roentogenol. 2004;182: 1259Y1265.
7. Tanaka YO, Okada S, Satoh T, et al. Ovarian serous surface papillary borderline tumors form sea anemone-like masses. J Magn Reson Imaging. 2011;33: 633Y640.
8. Kataoka M, Togashi K, Koyama T, et al. MR imaging of Mullerian mucinous borderline tumors arising from endometriotic cysts. J Comput Assist Tomogr. 2002;26:532Y537.
9. Bazot M, Haouy D, Darai E, et al. Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours? Clin Radiol. 2013;68:e1Ye8.
10. deSouza NM, O'Neill R, Mclndoe GA, et al. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage 1 disease. AJR Am J Roentgenol. 2005;184:999Y1003.
11. Okamoto Y, Tanaka YO, Tsunoda H, et al. Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR. J Magn Reson Imaging. 2007;26:94Y99.
12. Bent CL, Sahdev A, Rockall AG, et al. MRI appearances of borderline ovarian tumours. Clin Radiol. 2009;64:430Y438.
13. Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;10:761Y767.
14. Kawahara K, Yoshida Y, Kurokawa T, et al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr. 2004;28:505Y516.
15. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223:780Y788.
16. Rieber A, Nüssle K, Stöhr I, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am J Roentgenol. 2001;177: 123Y129.
17. Castellucci P, Perrone AM, Piucchio M, et al. Diagnostic accuracy of 18FFDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun. 2007;28:589Y595.
18. Kitajima K, Suzuki K, Senda M, et al. FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 2011;32:549Y553.
19. Yamamoto Y, Oguri H, Yamada R, et al. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Int J Gynaecol Obstet. 2008;102:124Y127.
20. Jung DC, Choi HJ, Ju W, et al. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynecol Cancer. 2008; 18:637Y641.
21. Risum S, Høgdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancerVa prospective study. Gynecol Oncol. 2007;105:145Y149.
22. Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol. 2010;116:389Y394.
23. Yang ZY, Hu SL, Shi W, et al. The clinical value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in postoperative patients with gastrointestinal mucinous adenocarcinoma. Nucl Med Commun. 2011;32:1018Y1025.
24. Shim SS, Han J. FDG-PET/CT imaging in assessing mucin-producing nonYsmall cell lung cancer with pathologic correlation. Ann Nucl Med. 2010; 24:357Y362.
25. Takanami K, Hiraide T, Tsuda M, et al. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med. 2011;25:501Y510.
26. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
27. Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardization and quantification of FDG whole body PET studies in multicenter trials. Eur J Nucl Med Mol Imaging. 2008;35:2320Y2333.
28. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50:11Y20.
29. Morelli JN, Runge VM, Ai F, et al. Magnetic resonance evaluation of renal artery stenosis in a swine model. Invest Radiol. 2012;47:376Y382.
30. Tanaka YO, Nishida M, Kurosaki Y, et al. Differential diagnosis of gynecological ''stained glass'' tumours on MRI. Br J Radiol. 1999;72:414Y420.
31. Kang DE, White RL Jr, Zuger JH, et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806Y1809.
32. DeLair D, Oliva E, Köbel M, et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Pathol. 2011;35:36Y44.
33. Matsuoka Y, Ohtomo K, Araki T, et al. MR imaging of clear cell carcinoma of the ovary. Eur Radiol. 2001;11:946Y951.
34. Quick HH, von Gall C, Zeilinger M, et al. Integrated whole-body PET/MR hybrid imaging: clinical experience. Invest Radiol. 2013;48:280Y289.
35. Hartung-Knemeyer V, Beiderwellen KJ, Buchbender C, et al. Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging. Invest Radiol. 2013; 48:290Y294.
36. Nakajo K, Tatsumi M, Inoue A, et al. Diagnostic performance of fluorodeoxyglucose positron emission tomography/magnetic resonance imaging fusion images of gynecological malignant tumors: comparison with positron emission tomography/computed tomography. Jpn J Radiol. 2010;28:95Y100.
37. Takeuchi M, Matsuzaki K, Nishitani H. Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. J Comput Assist Tomogr. 2010;34:173Y176.
38. Thomassin-Naggara I, Toussaint I, Perrot N, et al. Characterization of complex adnexal masses: value of adding perfusion-and diffusion-weighted MR imaging to conventional MR imaging. Radiology. 2011;258:793Y803.
39. Lin C, Itti E, Luciani A, et al. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol. 2011;46:341Y349.
40. Esseridou A, Di Leo G, Sconfienza LM, et al. In vivo detection of choline in ovarian tumors using 3D magnetic resonance spectroscopy. Invest Radiol. 2011;46:377Y382